Dyne wins new Outperform at BMO on prospects for lead drug
Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.
Dyne Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...
The TRADE3d
Capital Markets in 2025: 10 transformative trends reshaping the industry
From artificial intelligence becoming a must-have capability to the rise of financial mega-factories, several key trends are reshaping how capital markets operate. Datos Insights’ Vinod Jain and Jay ...
Gateway Academy Receives Prestigious WASC Accreditation
Gateway Academy, a private school in Phoenix for "Twice Exceptional" students in grades 6-12, recently received accreditation from the ACS WASC.
SailPoint initiated with an Outperform at BMO Capital
BMO Capital analyst Keith Bachman initiated coverage of SailPoint (SAIL) with an Outperform rating and $26 price target The firm believes ...
Is the US headed for a recession? Here's what economists are saying
Tariffs present an inflationary risk, but bank economists see mostly smooth sailing, with steady growth, modest unemployment ...
Bank of Montreal: Fundamentally Solid, But Wait For Some Dips
Bank of Montreal remains a resilient investment with strong fundamentals, excellent diversification, and prudent management.